Indian pharmaceutical exporter to Morocco

We prepare the full French-language Common Technical Document in-house through our regulatory desk, including Module 1 administrative annexes, Module 2 quality and clinical summaries, and Module 3 quality data. We translate from the Indian manufacturer master file using regulatory-French conventions that DMP assessors read every day, which avoids the literal-translation pitfalls that trigger query letters. Most Moroccan importers work with us under a single commercial agreement that bundles the dossier and the supply commitment, so they do not have to manage a second consultant invoice or coordinate document handover between two parties.

Eight to twelve months is the practical window once the file is complete and accepted at administrative validation. Faster outcomes happen when the comparator product already sits on the Moroccan formulary and the dossier matches that comparator on indication, strength, and dosage form. Slower outcomes happen when stability data needs supplementation, when the manufacturing site has not been inspected by an EU-recognised regulator, or when LNCM raises analytical-method clarifications. We try to flag those risks during the gap analysis we run before filing rather than after the dossier enters review.

Single-molecule orders are common, particularly for oncology biosimilars and biologics where the importer is responding to a specific CHU tender award rather than building a broad book. We have no minimum portfolio requirement and no minimum order value beyond what makes commercial sense for a temperature-controlled shipment. For ambient solid orals we typically consolidate into a forty-foot container or a partial reefer, and for cold-chain biologics we run scheduled air freight at the volume the institutional customer needs.

Tanger Med is the faster customs gateway for most carrier strings out of Mumbai, especially since 2024 throughput crossed eleven million TEU and dwell times shortened. Casablanca handles the bulk of southbound distribution and offers more mature temperature-controlled handling at the Mohammed V cargo terminal for cold-chain consignments, which makes it the preferred entry point for biologics. We keep both options available on every shipment so a port disruption at either side does not delay an importer's release schedule.

Once a container clears customs, the importer files for LNCM release with the certificate of analysis, the registered-dossier reference, and physical samples drawn from the lot. LNCM verifies identity, assay, related substances, and dosage-form-specific tests against the registered specifications. Service-standard release is typically two to four weeks for a routine small-molecule lot and longer for biologics that need bioassay confirmation. We pre-position the analytical evidence the laboratory will reference, which keeps the file inside service-standard rather than triggering a re-test.

Oncology biosimilars, biologics, complex generics, second-line and last-line anti-infectives, transplant immunosuppressants, paediatric scarce strengths, and cold-chain biologics including insulins. These are the segments where Moroccan domestic manufacturing either has limited analytical depth or has not invested behind the molecule, which gives an Indian WHO-GMP supplier a defendable formulary position. We deliberately stay light on commodity solid orals where local manufacturers have a structural cost and political advantage, because that is not a market segment a foreign exporter wins on.

We invoice in EUR or USD against an irrevocable letter of credit issued by a Moroccan commercial bank, confirmed where the importer requests it. The Moroccan Dirham is fully convertible for trade, so settlement of import LCs from Bank Al-Maghrib member banks happens on standard timelines without political-risk overlay. For repeat customers with a working-credit history we move to documents-against-payment or open-account terms once a track record is established and the importer's bank confirms a clean settlement file.